Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Fernando Franco
Observed names:
F. Franco,
Fabio Franco,
Fernando F. Franco,
Fernando Fabio Franco,
Fernando Franco Franco,
Fernando Franco Pérez
show all 6
Institutions:
Hospital Universitario Puerta de Hierro Majadahonda,
MD Anderson Cancer Center Madrid
Observed institutions:
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia,
Hospital Universitario Puerta de Hierro Majadahonda,
Madrid Health Service,
MD Anderson Cancer Center Madrid,
Universidad Autónoma de Madrid,
Universidade Nova de Lisboa
show all 6
ORCID:
0000-0001-8964-5136
Observed ORCID:
0000-0001-8964-5136
OpenAlex ID:
A5004476887
Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non–Small-Cell Lung Cancer (NADIM phase II trial)
2022
·
Mariano Provencio
, Roberto Serna-Blasco
, et al.
·
Journal of Clinical Oncology
·
390
Cisplatin resistance involves a metabolic reprogramming through ROS and PGC-1α in NSCLC which can be overcome by OXPHOS inhibition
2019
·
Alberto Cruz-Bermúdez
, Raquel Laza-Briviesca
, et al.
·
Free Radical Biology and Medicine
·
214
PDF
To burn-out or not to burn-out: a cross-sectional study in healthcare professionals in Spain during COVID-19 pandemic
2021
·
Maria Torrente
, Pedro AC Sousa
, et al.
·
BMJ Open
·
160
PDF
Cancer-associated fibroblasts modify lung cancer metabolism involving ROS and TGF-β signaling
2018
·
Alberto Cruz-Bermúdez
, Raquel Laza-Briviesca
, et al.
·
Free Radical Biology and Medicine
·
150
PDF
Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping
2018
·
J. Zugazagoitia
, I. Ramos
, et al.
·
Annals of Oncology
·
89
Neoadjuvant chemo/immunotherapy for the treatment of stages IIIA resectable non-small cell lung cancer (NSCLC): A phase II multicenter exploratory study—NADIM study-SLCG.
2018
·
Mariano Provencio-Pulla
, Ernest Nadal-Alforja
, et al.
·
Journal of Clinical Oncology
·
72
Neoadjuvant chemo-immunotherapy for the treatment of stage IIIA resectable non-small-cell lung cancer (NSCLC): A phase II multicenter exploratory study—Final data of patients who underwent surgical assessment.
2019
·
Mariano Provencio
, Ernest Nadal
, et al.
·
Journal of Clinical Oncology
·
65
Monitoring of Circulating Tumor DNA Predicts Response to Treatment and Early Progression in Follicular Lymphoma: Results of a Prospective Pilot Study
2022
·
Ismael Fernández-Miranda
, Lucía Pedrosa
, et al.
·
Clinical Cancer Research
·
56
PDF
Blood biomarkers associated to complete pathological response on NSCLC patients treated with neoadjuvant chemoimmunotherapy included in NADIM clinical trial
2021
·
Raquel Laza‐Briviesca
, Alberto Cruz‐Bermúdez
, et al.
·
Clinical and Translational Medicine
·
54
Primary Breast Lymphoma: Analysis of 55 Cases of the Spanish Lymphoma Oncology Group
2016
·
Fernando Franco Pérez
, Javier Lavernia
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
·
50
Epidemiology, treatment, and survival in small cell lung cancer in Spain: Data from the Thoracic Tumor Registry
2021
·
Fernando Franco
, Enric Carcereny
, et al.
·
PLoS ONE
·
43
PDF
Lung cancer patients with COVID-19 in Spain: GRAVID study
2021
·
Mariano Provencio
, José María Mazarico Gallego
, et al.
·
Lung Cancer
·
41
PDF
Prognostic value of quantitative ctDNA levels in non small cell lung cancer patients
2017
·
Mariano Provencio
, María Torrente
, et al.
·
Oncotarget
·
39
PDF
Analysis of circulating tumour DNA to identify patients with epidermal growth factor receptor–positive non-small cell lung cancer who might benefit from sequential tyrosine kinase inhibitor treatment
2021
·
Mariano Provencio
, Roberto Serna-Blasco
, et al.
·
European Journal of Cancer
·
36
Mutational profile of primary breast diffuse large B-cell lymphoma
2017
·
Fernando Franco
, Julia González-Rincón
, et al.
·
Oncotarget
·
33
PDF
Usefulness of the MSG/IFICG/EORTC diagnostic criteria of invasive pulmonary aspergillosis in the clinical management of patients with acute leukaemia developing pulmonary infiltrates
2006
·
Erika Borlenghi
, Chiara Cattaneo
, et al.
·
Annals of Hematology
·
32
Phase II clinical trial with metronomic oral vinorelbine and tri-weekly cisplatin as induction therapy, subsequently concomitant with radiotherapy (RT) in patients with locally advanced, unresectable, non-small cell lung cancer (NSCLC). Analysis of survival and value of ctDNA for patient selection
2021
·
Mariano Provencio
, Margarita Majem
, et al.
·
Lung Cancer
·
27
Clinical outcomes of FOLFIRINOX and gemcitabine–nab paclitaxel for metastatic pancreatic cancer in the real world setting
2020
·
F. Franco
, J. C. Camara
, et al.
·
Clinical & Translational Oncology
·
22
On Predicting Recurrence in Early Stage Non-small Cell Lung Cancer.
2021
·
Sameh K Mohamed
, Brian Walsh
, et al.
·
PubMed
·
18
Integrating immune checkpoint inhibitors and targeted therapies in the treatment of early stage non-small cell lung cancer: a narrative review
2020
·
Ana Ortega-Franco
, Virginia Calvo
, et al.
·
Translational Lung Cancer Research
·
18
PDF
Use of immune checkpoint inhibitors in patients with solid tumors and pre-existing autoimmune or inflammatory disease: real-world data
2021
·
Virginia Calvo
, Marta Andrés Fernández
, et al.
·
Lung Cancer Management
·
17
Next-generation sequencing for tumor mutation quantification using liquid biopsies
2019
·
Mariano Provencio
, Clara Pérez-Barrios
, et al.
·
Clinical Chemistry and Laboratory Medicine (CCLM)
·
17
Concordance between circulating tumor cells and clinical status during follow-up in anaplastic lymphoma kinase (ALK) non-small-cell lung cancer patients
2017
·
Mariano Provencio
, David Pérez-Callejo
, et al.
·
Oncotarget
·
17
PDF
Assessing the risk of cardiovascular events in patients receiving immune checkpoint inhibitors
2022
·
María Torrente
, Mariola Blanco
, et al.
·
Frontiers in Cardiovascular Medicine
·
16
PDF
Clinical and molecular parameters associated to pneumonitis development in non-small-cell lung cancer patients receiving chemoimmunotherapy from NADIM trial
2021
·
Belén Sierra-Rodero
, Alberto Cruz-Bermúdez
, et al.
·
Journal for ImmunoTherapy of Cancer
·
16
PDF
Show more works
View as search
Works count:
79
Citation count:
1,833
H-index:
18
I10-index:
28
Year
Topic
Type